0 49

Cited 6 times in

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer

Authors
 Matteo Lambertini  ;  Marcello Ceppi  ;  Richard A Anderson  ;  David A Cameron  ;  Marco Bruzzone  ;  Maria Alice Franzoi  ;  Claudia Massarotti  ;  Sarra El-Abed  ;  Yingbo Wang  ;  Christophe Lecocq  ;  Paolo Nuciforo  ;  Rebecca Rolyance  ;  Lajos Pusztai  ;  Joohyuk Sohn  ;  Maria Maddalena Latocca  ;  Luca Arecco  ;  Barbara Pistilli  ;  Kathryn J Ruddy  ;  Alberto Ballestrero  ;  Lucia Del Mastro  ;  Fedro A Peccatori  ;  Ann H Partridge  ;  Cristina Saura  ;  Michael Untch  ;  Martine Piccart  ;  Serena Di Cosimo  ;  Evandro de Azambuja  ;  Isabelle Demeestere 
Citation
 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, Vol.21(1) : 33-41.e16, 2023-01 
Journal Title
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
ISSN
 1540-1405 
Issue Date
2023-01
MeSH
Adult ; Biomarkers ; Breast Neoplasms* / drug therapy ; Breast Neoplasms* / surgery ; Female ; Humans ; Lapatinib / therapeutic use ; Ovarian Reserve* ; Paclitaxel / adverse effects
Keywords
Anti-Mullerian hormone ; anti-HER2 therapy ; breast cancer ; gonadotoxicity ; paclitaxel
Abstract
BACKGROUND: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment-induced gonadotoxicity. PATIENTS AND METHODS: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the biological window of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy). RESULTS: The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33-42 years). AMH values at the 3 time points differed significantly (P<.001). At baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56-2.62 ng/mL). At week 2, a small but significant reduction in AMH levels was observed (median, 1.10 ng/mL; IQR, 0.45-2.09 ng/mL; P<.001). At surgery, a larger significant decline in AMH levels was observed (median, 0.01 ng/mL; IQR, 0.01-0.03 ng/mL; P<.001). Although the type of anti-HER2 treatment (trastuzumab and/or lapatinib) did not seem to impact the results, age and pretreatment ovarian reserve had a major influence on treatment-induced gonadotoxicity risk. CONCLUSIONS: This NeoALTTO biomarker analysis showed that anti-HER2 therapies alone had limited gonadotoxicity but that the addition of weekly paclitaxel resulted in marked AMH decline with possible negative implications for subsequent ovarian function and fertility.
Full Text
https://jnccn.org/view/journals/jnccn/21/1/article-p33.xml
DOI
10.6004/jnccn.2022.7065
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/198329
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links